Hyemi Kwon

Dr. Hyemi Kwon

Auto-generated profile, based on publicly available information

Dr. Hyemi Kwon


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Thyroid®
Verified
Journal Article
Closed access
MJMin Ji Jeon
Min Ji Jeon
WKWon Gu Kim
Won Gu Kim
YCYun Mi Choi
Yun Mi Choi
HKHyemi Kwon
Hyemi Kwon
YLYu-mi Lee
Yu-mi Lee
WKWon Bae Kim
Won Bae Kim
Background: The recent increase in the incidence of thyroid cancer has been mainly attributed to papillary thyroid microcarcinomas (PTMCs), and many studies have suggested conservative strategies for the diagnosis and treatment of PTMC. However, PTMCs may be associated with distant metastasis. This study aimed to evaluate the clinicopathological features and identify the risk factors for distant metastasis in patients with PTMCs. Methods: The medical records of 8808 patients who were diagnosed with PTMC from 1999 to 2012 were reviewed, and 12 (0.1%) patients with distant metastasis were identified. Forty-one PTMC patients who initially had lateral cervical lymph node (LN) metastasis and were cured with no evidence of a distant metastasis were also selected as a control group. Results: Of the 12 patients with distant metastasis, nine had synchronous metastasis and three had metachronous metastasis. All 12 patients had primary tumors >0.5 cm and cervical LN metastasis at initial surgery. Ten patients had clinically apparent lateral cervical LN metastases, while two patients had only microscopic involvement of a central LN. Four patients died of thyroid carcinoma. Disease-specific mortality was associated with old age, large metastatic LNs with extranodal extension, and aggressive pathologic subtype of metastatic LNs. When the clinicopathological features of the patients with distant metastasis were compared with the control patients, the presence of extranodal extension and change to an aggressive pathologic subtype of metastatic LNs were significantly associated with distant metastasis and persistent structural distant PTMC metastasis. Conclusions: Most patients with PTMC demonstrate excellent clinical outcomes, and distant metastases rarely occur. However, distant metastasis of PTMC can be fatal. Performing a meticulous pathologic examination of metastatic LNs to identify the presence of extranodal extension and the pathologic subtype of metastatic LNs helps to assess the risk of a distant metastasis in patients with PTMC.

1 April 2017 in Thyroid®
Verified
Journal Article
Closed access
SPSuyeon Park
Suyeon Park
WKWon Gu Kim
Won Gu Kim
ESEyun Song
Eyun Song
HOHye-Seon Oh
Hye-Seon Oh
MKMijin Kim
Mijin Kim
WKWon Bae Kim
Won Bae Kim
Background: Increased incidence of small differentiated thyroid cancer (DTC) has emphasized the need for risk stratification and individualized disease management for these low risk DTCs. The aim was to validate a new dynamic risk stratification (DRS) system for prediction of structural recurrent/persistent disease in patients with DTC treated without radioactive iodine (RAI) remnant ablation therapy. Methods: This historical cohort study included 357 patients with DTC treated with lobectomy or total thyroidectomy without RAI therapy. We stratified patient response to initial treatment as excellent, indeterminate, biochemical incomplete, and structural incomplete according to the DRS system. Results: During a median 8.6 year of follow-up, 3.6% patients had structural recurrent DTC. The response was excellent in 71.7% patients, indeterminate in 18.5%, biochemical incomplete in 8.4%, and structural incomplete in 1.4%. There were significant differences in disease-free survival among the DRS groups (p < 0.001). The hazard ratio (HR) of recurrent/persistent disease was significantly higher in biochemical incomplete group (HR = 20.8, p < 0.001) and structural incomplete group (HR = 243.3, p < 0.001) compared with the excellent group. However, the tumor node metastasis (TNM) staging system and the American Thyroid Association (ATA) initial risk classification did not effectively predict recurrence of DTC. Conclusions: The new DRS system was effective for predicting risk of recurrent/persistent disease in patients with DTC who underwent lobectomy or total thyroidectomy without RAI remnant ablation.

1 January 2018 in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
HKHyemi Kwon
Hyemi Kwon
JJJin-Hyung Jung
Jin-Hyung Jung
KHKyung-Do Han
Kyung-Do Han
YPYong-Gyu Park
Yong-Gyu Park
JCJung-Hwan Cho
Jung-Hwan Cho
WLWon-Young Lee
Won-Young Lee
Kwon H, et al. Endocrinol Metab. 2018 Jun;33(2):260-267. https://doi.org/10.3803/EnM.2018.33.2.260

1 March 2018 in Thyroid®
Verified
Journal Article
Closed access
HOHye-Seon Oh
Hye-Seon Oh
HKHyemi Kwon
Hyemi Kwon
ESEyun Song
Eyun Song
MJMin Ji Jeon
Min Ji Jeon
DSDong Eun Song
Dong Eun Song
WKWon Gu Kim
Won Gu Kim
Background Total thyroidectomy and cervical lymph node (LN) dissection is generally recommended in patients with medullary thyroid carcinoma (MTC). However, there is no clear evidence for whom to perform prophylactic lateral neck dissection in MTC patients without evident lateral cervical lymph node (LCLN) metastasis in preoperative images. This study evaluated the preoperative features for predicting the LCLN metastasis of MTC. Methods We included 26 MTC patients with LCLN metastasis at initial surgery (N1b group) and 47 MTC patients without any LN metastasis or recurrence of disease (N0-NED group). We evaluated the association between LCLN metastasis and preoperative clinical and sonographic characteristics (size, location, solid component, shape, margin, echogenicity, calcification, and subcapsular location of the tumor). Results There were no significant differences in age and sex between the N1b and N0-NED groups. Preoperative serum levels of calcitonin (Ctn) above 65 pg/mL were associated with LCLN metastasis (p < 0.001). In preoperative neck ultrasonography (US), patients in the N1b group were more commonly found with a larger tumor (>1.5 cm) of irregular shape with a spiculated margin and a subcapsular location than those in the N0-NED group (p = 0.029, p < 0.001, p < 0.001, and p < 0.001, respectively). Increases in the number of these LCLN metastasis-related features were significantly associated with higher risk for LCLN metastasis (p < 0.001). The presence of two or more predictors was an appropriate cut-off point for predicting LCLN metastasis of MTC with 73.1% sensitivity and 91.5% specificity. Conclusions MTC tumors with high preoperative Ctn levels (>65 pg/mL), larger size (>1.5 cm), irregular shape, spiculated margins, and subcapsular locations in the neck US are at higher risk for LCLN metastasis. MTC patents with less than two predictors might be suitable for treatment without prophylactic LCLN dissection.

1 May 2018 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
EREun-Jung Rhee
Eun-Jung Rhee
JCJung Hwan Cho
Jung Hwan Cho
HKHyemi Kwon
Hyemi Kwon
SPSe Eun Park
Se Eun Park
CPCheol-Young Park
Cheol-Young Park
WLWon-Young Lee
Won-Young Lee

1 January 2016 in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
HKHyemi Kwon
Hyemi Kwon
MEMarkus Eszlinger
Markus Eszlinger
RPRalf Paschke
Ralf Paschke
DSDong Eun Song
Dong Eun Song
MKMijin Kim
Mijin Kim
WKWon Gu Kim
Won Gu Kim
Kwon H, et al. Endocrinol Metab. 2016 Dec;31(4):586-591. https://doi.org/10.3803/EnM.2016.31.4.586